FDA issues warning against 'microdosing' chocolate bars that sent 6 to the hospital

Lauren Edmonds
·2 min read
15
FDA issues warning against 'microdosing' chocolate bars that sent 6 to the hospital

  • The FDA is investigating Diamond Shruumz-brand microdosing chocolate bars.

  • Eight people fell ill after consuming the product, the agency said.

  • The symptoms included vomiting, seizures, and central nervous system depression.

Eight people in four states fell ill after consuming Diamond Shruumz-brand microdosing chocolate bars, the FDA said on Friday.

Microdosing is the practice of regularly taking a dose of a drug — typically a psychedelic — that is small enough not to feel any effect.

Some people believe microdosing can improve creativity and mental health. It's become trendy in Silicon Valley. And some CEOs say they've added microdosing to their morning routine.

The microdosing industry has boomed in recent years as companies hope to transform drugs like MDMA into approved medicines. Business Insider reported that a "psychedelics renaissance" began sweeping the industry in 2020. Data from Pitchbook said psychedelics companies amassed $163.6 million in investments during the first three quarters of 2020.

While Diamond Shruumz markets its products as microdoses, they don't actually contain any psychedelics. The company sells more than a dozen products, including chocolate bars that come in six flavors. The company's FAQ said its products use a "proprietary blend of natural ingredients."

"There is no presence of psilocybin, amanita, or any scheduled drugs, ensuring a safe and enjoyable experience," its website says. "Rest assured, our treats are not only free from psychedelic substances, but our carefully crafted ingredients still offer an experience."

The FDA said people experienced "severe symptoms" after eating the chocolate bars, including seizures, central nervous system depression, nausea, vomiting, agitation, abnormal heart rates, and hyper/hypotension.

All eight who fell ill sought medical care. Six had to be hospitalized, but there were no reported deaths.

"FDA is working to determine the cause of these illnesses and is considering the appropriate next steps. More information will be provided as it becomes available," the news release said.

Representatives for Diamond Shruumz did not respond to Business a request for comment from Business Insider.

Read the original article on Business Insider